

# DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

April 21, 2021  
MO HealthNet

[Join Webex Meeting](#)

Meeting number (access code): 177 549 2307

Join from a video system or application

Dial [1775492307@stateofmo.webex.com](tel:1775492307)

You can also dial 173.243.2.68 and enter your meeting number.

Tap to join from a mobile device (attendees only)

[+1-650-479-3207](tel:+16504793207) Call-in toll number (US/Canada)

[\\* Click HERE for Meeting Documents \\*](#)

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	Review of Prior Authorization Meeting and Public Hearing	Josh Moore
	<b>Old Business</b>	
10:35 – 10:45	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
	<b>New Business</b>	
10:45 – 11:00	Proposed Actions - New Drug/Product Review (See Website and Attached Summary) <ul style="list-style-type: none"><li>i. Open Access</li><li>ii. Clinical Edit/Step Therapy</li><li>iii. PDL Agents</li><li>iv. Prior Authorization</li></ul>	Josh Moore
11:00 – 11:45	<b>Clinical and Fiscal Edits</b> <u>Existing Criteria</u> <ul style="list-style-type: none"><li>i. Acne or Rosacea, Select Topical Agents</li><li>ii. Givlaari</li><li>iii. Megestrol</li><li>iv. Sickle Cell Disease</li><li>v. Systemic Antifungals</li><li>vi. Zulresso</li></ul> <u>New Criteria or Revision of Existing Criteria</u> <ul style="list-style-type: none"><li>i. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators</li><li>ii. Clobazam Agents</li><li>iii. Fabry Disease</li><li>iv. Nocturnal Polyuria</li><li>v. Opioids, Single Agents Short Acting</li><li>vi. Oxlumo</li><li>vii. Spravato</li></ul>	Josh Moore

11:45 – 1:00

**Preferred Drug List (PDL)**

Josh Moore

Existing Criteria

- i. Actinic Keratosis Agents, Topical
- ii. Antifungals, Oral
- iii. Antihistamines, Intranasal
- iv. Antihistamines/Decongestant Combinations, Second Generation
- v. Antivirals, Oral
- vi. Antivirals, Topical
- vii. Benzoyl Peroxide/Antibiotic Combinations
- viii. Beta Adrenergic Agents, Long Acting
- ix. Beta Adrenergic Agents, Nebulized
- x. Cough/Cold Preparations
- xi. Fluoroquinolones, Ophthalmic
- xii. Mast Cell Stabilizers, Ophthalmic
- xiii. NSAIDs, Ophthalmic
- xiv. Pancreatic Enzymes
- xv. Psoriasis Agents, Oral
- xvi. Psoriasis Agents, Topical
- xvii. Retinoids, Topical
- xviii. Ulcerative Colitis Agents, Rectal

New Criteria or Revision of Existing Criteria

- i. Androgenic Agents
- ii. Antibiotics, Inhaled
- iii. Antifungals, Topical
- iv. Antihistamines, Ophthalmic
- v. Antiparasitics, Topical
- vi. Atopic Dermatitis Agents, Immunomodulators
- vii. Beta Adrenergic Agents, Short Acting
- viii. COPD Agents
- ix. Corticosteroids, Inhaled
- x. Corticosteroids, Intranasal
- xi. Corticosteroids, Ophthalmic Soft
- xii. Corticosteroids, Topical
- xiii. Epinephrine Agents, Self-Injectable
- xiv. Fluoroquinolones, Otic
- xv. Glaucoma Agents
- xvi. Hepatitis C Agents PDL Edit
- xvii. Hereditary Angioedema (HAE) Agents
- xviii. Leukotriene Receptor Modifiers
- xix. Respiratory Monoclonal Antibodies
- xx. Ulcerative Colitis, Oral

1:00 – 1:15

**LUNCH**

1:15 – 1:30

**Program Utilization Information – Conduent Update**

Jennifer Colozza

- i. Call Center Statistics
- ii. CyberAccess User Statistics
- iii. New Drug Statistics
- iv. “Top 25” Drugs by Cost/Claims

1:30 – 1:50

**Other Business**

- i. Sedative Hypnotic PDL Edit Changes Impact Report

*Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly.*

**NEXT MEETING: July 21, 2021**

Meeting via Webex unless  
otherwise specified